Introduction The NF-κB transcription factor protein family has diverse cellular and biological functions, and posttranslational modification is important to regulate these functions. An important site of phosphorylation of NF-κB p65 subunit is at serine-536 (phospho-Ser536-p65), and this phosphorylation is involved in regulation of transcriptional activity, nuclear localization, and protein stability. Patients and Methods In this study, we investigated expression of phospho-Ser536-p65 in colorectal cancers and its relationships with clinicopathological factors. The expression of phospho-Ser536-p65 was examined by immunohistochemistry in 203 primary colorectal cancers, 156 normal mucosa specimens, and 18 metastases in the lymph nodes. Results The expression of phospho-Ser536-p65 increased from normal mucosa to primary tumor (p<0.0001). Further, the increased expression of phospho-Ser536-p65 in the cytoplasm of the primary tumors correlated with worse survival of the patients independently of gender, age, tumor location, stage, and differentiation (p=0.04; hazard ratio, 1.89; 95% CI 1.03-3.47). Conclusion The NF-κB p65 subunit phosphorylated at serine-536 is an independent prognostic factor in colorectal cancer patients.
Introduction
Colorectal cancer is one of the most common forms of cancers after prostate and breast cancer in the Western world. Despite extraordinary progress in survival due to improved diagnosis and especially treatment, many patients still suffer from recurrence and eventually die from the cancer. There is significant variation in the response to the treatments and survival among patients even though they have the tumor in the same stage [1] . Therefore, it is very important to search for more biological markers to identify patient survival and the response to treatments.
The NF-κB transcription factor protein family is involved in numerous cellular activities that, if not kept in balance, will transform the cell into a cancer cell [2, 3] . Five members of the family have been found in human cells: RelA (p65), p105/p50, p100/p52, RelB, and c-Rel. The most common form in human cells is p65/p50 heterodimer [2, 4, 5] . The regulation of the NF-κB protein family is very important. Dimers of NF-κB are kept in the cytoplasm in the cells in an inactive state by binding to inhibitory proteins. Upon activation, inhibitory proteins are degraded, and the proteins are translocated into the nucleus where they exert their effect. The regulation also occurs at the posttranslational level, where protein phosphorylation of the different subunits is a very important mechanism of regulation. Several different phosphorylation sites on the subunits have been discovered. An important site of phosphorylation of p65 subunit is at serine-536 (phosphoSer536-p65), and this phosphorylation is involved in regulation of transcriptional activity, nuclear localization, and protein stability [6] [7] [8] [9] . Studies have shown that the phospho-Ser536-p65 can be found in both the cytoplasm and the nucleus depending on the stimulus, and the phosphorylation is probably also cell-type specific [4, [10] [11] [12] .
In the light of recent knowledge of the importance of regulation of NF-κB activity through phosphorylation, we wanted to investigate whether expression of phosphoSer536-p65 was related to colorectal cancer development, especially to clinicopathological variables, including survival, in patients.
Materials and methods

Patients
Formalin-fixed paraffin-embedded tissue blocks were obtained from 203 patients with primary colorectal adenocarcinoma as the patients underwent surgical resection at Linköping Hospital or Vrinnevi Hospital between 1972 and 2004. The study also included 156 normal mucosa specimens (of them, 128 were matched with the primary tumors), taken from either the margin of distant resection or adjacent to the primary tumors, and 18 metastases in the lymph nodes (12 of them were matched with the primary tumors). The patients' gender, age, tumor location, stage, and differentiation (better differentiation including well and moderate differentiation and poorer differentiation including poor differentiation, mucinous, and signet-ring cell carcinomas) were obtained from surgical and/or pathological records at Linköping and Vrinnevi Hospitals. All patients were followed up, and the mean period of the follow-up was 77 months (median, 56 months, and range, 0.06-288 months), the data were received/confirmed from/ by surgeons and an oncologist as well as the staff at the Swedish Cancer Register Center, and the follow-up information was updated at least annually. The survival analyses were based on overall survival.
Immunohistochemistry
Five-micrometer sections were deparaffinized in xylene and rehydrated in graded ethanol. The method for antigen retrieval we used was high-pressure cooking in 0.01 M Tris-EDTA buffer (pH 9.0). The sections were heated to 125°C for 30 s and then cooled to 90°C for 10 s; the sections were then kept in the buffer until room temperature. The sections were incubated with 3% H 2 O 2 -methanol for 20 min and washed with phosphate-buffered saline (PBS, pH 7.4). After that the sections were incubated with rabbit anti-phospho-Ser536-p65 antibody (Abcam, MA; the antibody binds specifically to the Ser536-phosphorylated form of p65 and does not cross-react with nonphosphorylated p65 or any other members of the NF-κB family) at 20 mg/ml in antibody diluent (Dako, Carpinteria, CA) overnight, followed by rinsing with PBS. Subsequently, the sections were incubated with a goat anti-rabbit secondary antibody coupled with peroxidase provided by the Dako ChemMate EnVision Detection Kit (Dako) for 25 min and washed with PBS. The peroxidase reaction, using 3,3′-diaminobenzidine tetrahydrochloride (Dako), was performed for 8 min. Sections known to stain positively were included as positive controls. The negative controls used PBS instead of the primary antibody. In all staining procedures, the positive controls showed clear staining, and there was no staining in the negative controls.
The sections were microscopically examined and scored independently by Lewander A. and Gao J. without any information on the clinicopathological data. The slides were initially classified, in a subjective matter, as negative (<5% of positive cells), weak, moderate, and strong staining in the cytoplasm of normal epithelial cells, and tumor cells located in the entire area or invasive margin of the primary tumor and metastasis, irrespective of the percentage of positive cells. For statistical analysis, we combined the negative cases with weak-stained cases as a group called weak expression and combined moderate-and strongstained cases as a group called strong expression, based on the similarities of the clinicopathological features. The expression in the nucleus of normal epithelial and tumor cells was classified as negative (<5% of the nucleus stained) or positive expression. To avoid artificial effects, cells in areas with necrosis, with poor morphology, or in the margins of sections were excluded from the analysis.
Statistical analysis
The significance of the difference in phospho-Ser536-p65 expression between normal mucosa, primary tumor, and metastasis was tested by using McNemar methods. The relationships between phospho-Ser536-p65 expression and clinicopathological variables were tested by the Pearson chisquare method, and the relationships to survival were examined by using the Wald Cox's proportional hazard model. Survival curves were calculated by using the Kaplan-Meier method. In the survival analyses, only patients who died from colorectal cancer were classified as events, while those who died from other causes or were still alive were considered as censored. Two-sided p values <0.05 were considered statistically significant.
Results
Phospho-Ser536-p65 expression in the cytoplasm of normal mucosa, primary tumor, and metastasis in the lymph node Table 1 presents the frequency of phospho-Ser536-p65 cytoplasmic expression in normal mucosa, the entire primary tumor, the invasive margin of the primary tumor (excluding 27 cases that did not have a visible invasive margin), and metastasis in the lymph node. We compared the staining intensity of phospho-Ser536-p65 in normal mucosa with the entire primary tumor in the 128 matched cases by using the McNemar test. There were significantly more samples having strong expression among the primary tumors compared to normal mucosa (p<0.0001), i.e., among the 128 cases, 56 cases had weak expression in normal tissue but strong expression in tumor; in contrast, only five cases had strong expression in normal tissue, but weak expression in the tumor. The rest (67 cases) had identical expression in both normal and tumor tissue. There was no significant difference in the frequency of the expression between entire primary tumors and metastasis in the 12 matched cases (p=0.22).
We also compared the staining intensity of phosphoSer536-p65 in normal mucosa with that in the invasive margin of the primary tumor by using the McNemar test; the results were similar to a comparison of the normal mucosa with the entire primary tumor, i.e., the frequency of the strong staining was higher in the invasive margin of the primary tumor than in normal mucosa (p<0.0001). Figure 1 shows phospho-Ser536-p65 expression in normal mucosa, primary tumor, and metastases in the lymph node. There was no phospho-Ser536-p65 expression in normal mucosa, but there was strong expression in the cytoplasm of primary and metastatic tumors.
Phospho-Ser536-p65 expression in the cytoplasm in relation to clinicopathological variables We first analyzed the relationship of cytoplasmic phosphoSer536-p65 expression in the entire area of the primary tumor with survival. Univariate survival analysis showed that the strong expression of the phospho-Ser536-p65 correlated with worse survival of the patients (p=0.02, Fig. 2 ). In the further multivariate analysis, the prognostic significance still remained after adjusting for patients' gender, age, tumor location, stage, and differentiation (p= 0.04; hazard ratio, 1.89; 95% CI 1.03-3.47; Table 2 ). However, we did not find any statistically significant relationship of the phospho-Ser536-p65 expression with gender, age, tumor location, stage, or differentiation by using the Pearson chi-square method (p>0.05, data not shown).
Then we analyzed the relationship of cytoplasmic phospho-Ser536-p65 expression in the invasive area of the primary tumor with survival. In the multivariate analysis, strong expression of the phospho-Ser536-p65 in the invasive margin of tumors was also related to worse survival independently of tumor stage (p=0.04, data not shown). However, the prognostic significance was lost when we included patients' gender, age, tumor location, and differentiation (p=0.13, by the Wald multivariate Cox regression analysis, data not shown).
Expression of phospho-Ser536-p65 in the nucleus
There was a clear positive relationship between phosphoSer536-p65 expression in the cytoplasm and that in the nucleus (p<0.001, by using the Pearson chi-square test, Table 3 ).
There was no statistical difference in the frequency of phospho-Ser536-p65 expression in the nuclei from normal mucosa to primary tumors (p=0.20, by McNemar test) and from the primary tumor to metastasis in the lymph node (p= 0.29, by McNemar test), neither with survival by using Wald Cox's proportional hazard model (p=0.64, Fig. 2b ) nor other clinicopathological variables by using the Pearson chi-square method (p>0.05, data not shown).
Discussion
NF-κB regulates the transcription of many genes which are responsible for immune response, cell adhesion, differentiation, proliferation, angiogenesis, and apoptosis [2, 11] . Abnormalities in NF-κB regulation are involved in multiple . Since NF-κB is responsible for the regulation of many other genes, changed expression of the NF-κB and IκB proteins could be potentially involved in tumor development. In the present study, we found that expression of NF-κB p65 phosphorylated at serine-536 was increased in the primary tumor compared to normal mucosa. However, the frequency of the protein expression in the metastases in lymph nodes was not different from the primary tumor. Unregulated NF-κB in the primary tumor compared with normal tissue has been found in previous studies. Lind et al. [13] used an electrophoretic mobility shift assay technique and demonstrated that NF-κB in the primary tumor was greatly increased compared with adjacent normal tissue from the same patients. Yu et al. [14] examined the expression of NF-κB p65 by using a monoclonal antibody against NF-κB p65 in normal colorectal mucosa, colorectal adenomas, and colorectal adenocarcinomas and showed that NF-κB p65 expression was significantly increased from normal mucosa to adenoma and to adenocarcinoma; furthermore, the expression was increased with the transition from low to moderate and to high dysplasia of adenoma. Taken together, these results indicate that the NF-κB p65 may play a role in earlier development of colorectal cancer. The most interesting finding in the present study, also the first report, is that the expression of phospho-Ser536-p65 in the cytoplasm was significantly correlated to survival in the patients with colorectal cancer. The strong expression predicted worse survival of the patients independently of patients' gender, age, tumor location, stage, and differentiation. Even though the p value is marginal (p=0.04), the hazard ratio 1.89 (95% CI 1.03-3.47) is nearly two times higher when comparing the strong expression with the weakexpression group.
Unexpectedly, the NF-κB p65 in the nucleus did not give clinicopathological significance. Several other studies in colorectal and pancreatic cancers also showed cytoplasmic expression of NF-κB p65, and further experiments demonstrated that the majority of NF-κB p65 which is freed from IκB remained in the cytoplasm [14] [15] [16] . During activation, NF-kB p65 is phosphorylated at several residues. What residues, when, and where seem to be dependent on different stimuli that activate NF-kB [4] . There was a clear positive relationship between phospho- Ser536-p65 expression in the cytoplasm and that in the nucleus in the present study (p<0.001, Table 3 ). It may suggest that when the phosphorylated cytoplasmic NF-κB is accumulated to a certain level, it will transfer to the nucleus. We did not see a direct relationship between nuclear NF-κB and survival, which may depend on a matter of time point and/or the number of the cases, etc. In fact, in the survival curves of the nuclear NF-κB, we saw a trend of the positive NFκB expression resulting in worse survival (similar to the cytoplasmic expression in relation to survival). Sakurai et al. [6] was the first to report that upon tumor necrosis factor-alpha-induced activation, IκB kinase phosphorylates NF-κB p65 at serine-536 and that this occurs in the cytoplasm of HeLa cells before activated p65 translocates into the nucleus. Our present result showing the cytoplasmic staining by the antibody against phospho-Ser536-p65 further confirmed that phosphorylated NF-κB p65 was in the cytoplasm of colorectal cancers, as well as in the nucleus. It has been shown that even under long-term stimulation, only up to 20% of NF-κB p65 moved to the nucleus, and the rest of the NF-κB p65 still remained in the cytoplasm [16] . Possible explanations for this phenomenon are (1) IκB is mutated and lost its binding to NF-κB p65 and masks the nuclear translocation signal in NF-κB p65 and (2) NF-κB p65 is mutated and inhibited its binding to IκB. Either mutation in IκB or NF-κB p65 prohibits their interaction, resulting in the changed activation and mislocalization of NF-κB p65. We did not exclude a possibility that other biological factors which are related to cytoplasmic NF-κB p65 play a role (or more important role) in colorectal cancer development/survival, rather than the cytoplasmic NF-κB p65 itself, i.e., the cytoplasmic NF-κB p65 may be a secondary event (as a bystander effect) due to co-activation of other biological factors. In summary, we found increased levels of NFκB p65 phosphorylated at serine-536 in the cytoplasm of primary tumors compared with normal mucosa in colorectal cancer patients; however, we did not see a further increase from primary tumors to metastases in the lymph nodes, indicating that upregulation of this protein is an early event in the development of colorectal cancer. Further, the cytoplasmic expression of NF-κB p65 phosphorylated at serine-536 predicts a worse prognosis independent of patients' gender, age, tumor location, stage, and differentiation.
